The Buprenorphine HCl 8.84 mg Oral Troche is a square-shaped solid dosage form that is designed to dissolve slowly in the mouth. This formulation allows for the medication to be absorbed through the oral mucosa, providing targeted local or systemic effects. Buprenorphine HCl is commonly used in the treatment of chronic pain and opioid dependence.

Licensed to fill prescriptions for patients in RI, MA, CT, NY, NJ, NH, FL and ME.
Prescriber? Sign in or create an account for prescription details and order forms.
Buprenorphine HCl 8.84 mg Oral Troche is a square-shaped solid dosage form that is designed to dissolve slowly in the mouth. The medication is delivered through the oral mucosa, allowing for targeted local or systemic effects.
Buprenorphine is a powerful opioid medication used to treat severe pain. It works by changing the way the brain and nervous system respond to pain. It binds to the body's opioid receptors, blocking the sensation of pain. This medication is also used as part of a complete treatment program for drug abuse (e.g., compliance monitoring, counseling, behavioral contract, lifestyle changes).
The 8.84 mg dosage of Buprenorphine HCl in this troche formulation is a potent dose, suitable for patients with severe pain conditions or those who have developed a tolerance to lower doses of opioids. It is important to note that this medication should only be used under the supervision of a healthcare professional due to the risk of addiction and misuse.
Patients using this formulation should allow the troche to dissolve slowly in the mouth without chewing or swallowing. This allows the medication to be absorbed directly into the bloodstream through the oral mucosa, providing rapid pain relief. Side effects may include nausea, vomiting, constipation, lightheadedness, dizziness, or drowsiness. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Prescribers should be aware that Buprenorphine HCl 8.84 mg Oral Troche is a Schedule III controlled substance, meaning it has potential for moderate to low physical dependence or high psychological dependence. It is crucial to monitor patients closely for signs of misuse, abuse, and addiction. Regular follow-ups and patient education about the risks and proper use of this medication are essential components of a successful treatment plan.
If you have any questions about this formulation, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is always here to assist you.
Buprenorphine HCl 8.84 mg Oral Troche is a potent opioid medication used primarily for the treatment of moderate to severe pain, and also in the management of opioid dependence. It works by binding to the opioid receptors in the brain, thereby reducing the perception of pain. This medication is formulated as a troche, a square-shaped solid dosage form that dissolves slowly in the mouth, allowing for the medication to be absorbed through the oral mucosa for targeted local or systemic effects.
Some of the key drug interactions to be aware of include:
Central Nervous System (CNS) Depressants: Co-administration of Buprenorphine with other CNS depressants, such as benzodiazepines, alcohol, or other opioids, can result in additive CNS depressant effects. This can lead to serious side effects such as respiratory depression, profound sedation, coma, or even death. If concurrent use is necessary, the dose of one or both medications should be reduced.
Antiretroviral Drugs: Certain antiretroviral drugs, such as ritonavir, can increase the levels of Buprenorphine in the body, potentially leading to increased side effects. Close monitoring for signs of opioid toxicity is recommended when these medications are used together.
Anticholinergic Drugs: The concomitant use of Buprenorphine with anticholinergic drugs can increase the risk of urinary retention and constipation. Patients should be monitored for these side effects and the dose of one or both medications may need to be adjusted.
Antifungal Agents: Some antifungal agents, such as ketoconazole, can increase the levels of Buprenorphine in the body, potentially leading to increased side effects. Close monitoring for signs of opioid toxicity is recommended when these medications are used together.
It's important to note that this is not an exhaustive list of all potential drug interactions. Patients should always inform their healthcare provider of all medications they are currently taking, including prescription drugs, over-the-counter medications, and dietary supplements. Similarly, prescribers should carefully consider the potential for drug interactions when prescribing Buprenorphine HCl 8.84 mg Oral Troche.
If you have any questions about Buprenorphine HCl 8.84 mg Oral Troche, its uses, or potential drug interactions, please don't hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is always here to help.
Buprenorphine HCl 8.84 mg Oral Troche is a unique formulation designed to deliver medication slowly and directly through the oral mucosa, the lining of the mouth. This method of delivery allows for the medication to be absorbed directly into the bloodstream, bypassing the digestive system and liver metabolism, which can often lead to a reduction in side effects and an increase in the effectiveness of the medication.
Buprenorphine is a partial opioid agonist, which means it binds to the opioid receptors in the brain, but it does not fully activate them. This helps to relieve pain and can also help with opioid withdrawal symptoms. The 8.84 mg dosage is a potent dose that can provide significant relief for moderate to severe pain, and can also be used in the treatment of opioid dependence.
The square-shaped solid dosage form is designed to dissolve slowly in the mouth. This allows for a steady release of the medication over a period of time, providing consistent relief without the peaks and troughs often associated with other forms of medication delivery. The slow dissolution also allows for the medication to be absorbed directly through the oral mucosa, providing a faster onset of action than other oral dosage forms.
When used in the treatment of pain, Buprenorphine HCl 8.84 mg Oral Troche can provide significant relief for patients suffering from conditions such as chronic pain, cancer pain, and post-operative pain. In the treatment of opioid dependence, it can help to reduce withdrawal symptoms and cravings, making it easier for patients to stop using opioids.
Patients should also be aware that this medication can cause drowsiness and should not be taken before driving or operating heavy machinery.
If you have any questions about Buprenorphine HCl 8.84 mg Oral Troche, or if you would like more information about how it works, please don't hesitate to reach out to us at Bayview Pharmacy. Our team of knowledgeable compounding pharmacists is always here to help.
In addition to its conventional use, Buprenorphine HCl 8.84 mg Oral Troche could potentially provide relief for alternative clinical applications. It could be used as an alternate for patients who have difficulty swallowing pills or who may be on a strict no-water medication routine. Due to its transmucosal absorption, it can be considered for patients suffering from nausea or vomiting, where oral medication ingestion is not suitable. This can be particularly valuable in palliative care, geriatric, and pediatric settings.
Furthermore, Buprenorphine acts as a partial agonist at opioid receptors, thus indicating its potential use for the management of pain in patients who have either failed traditional pain management techniques or experienced intolerable side effects. However, prescribers should keep in mind that despite buprenorphine's positive pain management attributes, the drug also carries risks for abuse and dependence, requiring close monitoring and patient education.
This formulation is also beneficial for chronic pain management where around-the-clock analgesic effect is required. The troche formulation provides sustained release and consistent pain relief, improving patient compliance and quality of life. However, buprenorphine troches should not be used as a first-line therapy for acute pain due to its slow onset of action.
There's also potential for this oral troche formulation in the treatment of Opioid Use Disorders, due to the drug's ceiling effect on opioid receptors reducing the risk of overdose, its long half-life promoting adherence, and oral administration reducing the risk of needle-related diseases. However, it’s essential for patients and prescribers to know that this use requires a special licensing and training due to its potential for abuse and diversion. Prescribers contemplating the use of buprenorphine in this context should always take into account both the potential benefits and risks, speaking openly with patients about these factors.
Ultimately, all potential uses of Buprenorphine HCl 8.84 mg Oral Troche should be considered within the context of individual patients' needs, their full medical and physiological conditions, and current other medications used. It is essential to monitor patients' response to medication and adjust the dose appropriately. If you have further queries or need more advice on this formulation, feel free to reach out to us at Bayview Pharmacy.
Buprenorphine HCl 8.84mg Oral Troche is a specific dosage and formulation of Buprenorphine, a medication used for pain relief. It is uniquely formulated into a square-shaped solid dosage form which dissolves slowly in the mouth.
This medication delivers its active ingredient, Buprenorphine, through the oral mucosa, the lining of the mouth. This allows for targeted local or systemic effects, depending on the need of the patient.
The troche is designed to dissolve slowly in the mouth. The duration can vary per individual and the rate of salivation, it is generally designed to allow for extended-release delivery of the medication.
Yes, you should not swallow, crush, or chew the troche. The troche should be placed in the mouth, usually under the tongue or in the cheek pouch and allowed to dissolve completely. Do not eat or drink anything until the troche has completely dissolved.
Side effects will vary between individuals and may include dizziness, drowsiness, headache, sweating, constipation, or dry mouth. Seek immediate medical attention if any severe side effects occur.
No. The suitability of this medication is determined by your healthcare provider, based on your medical history, current medications and condition. It should not be used by certain patients e.g., pregnant women or individuals with certain medical conditions.
Thus, it is advisable to allow it to dissolve in the mouth for optimal effect.
No, the Buprenorphine Oral Troche should not be split, crushed or chewed. It’s designed to be dissolved slowly in the mouth to ensure a gradual release of the medication.
If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Never double the dose to catch up. Always consult your healthcare provider if you are uncertain.
No, you should not eat or drink anything until the troche has completely dissolved in your mouth. Eating or drinking can interfere with the absorption of the medication.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
The conditions listed on this page are indications prescribers have ordered this preparation for. They are not FDA-approved indications, and listing them is not a statement that this preparation is effective for them.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice — discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NY, NJ, NH, FL, and ME. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 troche between cheek and gum and let slowly dissolve